P8RI

P8RI (D-P8RI) is a biomimetic peptide of CD31 and a CD31 agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway.

Product information

CAS Number: 2147724-76-1

Molecular Weight: 1016.24

Formula: C51H77N13O9

Chemical Name: (2R)-5-carbamimidamido-2-[(2R)-2-[(2R)-2-[(2R)-2-[(2R)-2-{[(2R)-1-[(2R)-2-[(2R)-2, 6-diaminohexanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}propanamido]-4-methylpentanamido]-3-phenylpropanamido]-3-methylbutanamido]pentanoic acid

Smiles: C[C@@H](NC(=O)[C@H]1CCCN1C(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](N)CCCCN)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC1C=CC=CC=1)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCNC(N)=N)C(O)=O

InChiKey: LXYOOXZYRDPHLW-PJJIIYKISA-N

InChi: InChI=1S/C51H77N13O9/c1-29(2)25-38(45(67)61-39(26-32-15-7-6-8-16-32)46(68)63-42(30(3)4)48(70)59-37(50(72)73)20-13-23-56-51(54)55)60-43(65)31(5)58-47(69)41-21-14-24-64(41)49(71)40(62-44(66)35(53)18-11-12-22-52)27-33-28-57-36-19-10-9-17-34(33)36/h6-10,15-17,19,28-31,35,37-42,57H,11-14,18,20-27,52-53H2,1-5H3,(H,58,69)(H,59,70)(H,60,65)(H,61,67)(H,62,66)(H,63,68)(H,72,73)(H4,54,55,56)/t31-,35-,37-,38-,39-,40-,41-,42-/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: To be determined

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

P8RI (D-P8RI) was designed as a retro-inverso peptide with all-D-amino acids allowing to maintain bioactivity and to confer resistance towards plasma proteases.

In Vivo:

P8RI (2.5 mg/kg; s.c.; daily from 7 to 28 after the occurrence of ADIM) prevents aneurysmal transformation by promoting the resolution of intramural hematoma and the production of collagen in dissected aortas in vivo, associated with enrichment of M2 macrophages at the site of injury.

References:

1. Andreata F, et al. Macrophage CD31 Signaling in Dissecting Aortic Aneurysm. J Am Coll Cardiol. 2018;72(1):45-57.
2. Sannier A, et al. A CD31-Derived Peptide Prevents the Development of Antibody-Mediated Lesions in a Rat Model of Aortic Allograft. Transplant Proc. 2021;53(2):746-749.

Products are for research use only. Not for human use.